Dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban are direct oral anticoagulants
(DOACs). Their inter-individual variability in pharmacodynamics and pharmacokinetics …

The economic and health burden caused by adverse drug reactions has increased
dramatically in the last few years. This is likely to be mediated by increasing polypharmacy …

Rivaroxaban is an anticoagulant drug that prevents forming of blood clots. In addition, it can
be administered to prevent and treat thrombotic diseases such as atrial fibrillation, cardiac …

Concomitant use of direct oral anticoagulants (DOACs) and medications with
inhibition/induction effect on P‐gp/CYP3A might increase risk of bleeding/treatment failure …

A large body of evidence suggests that not only direct anticoagulant effects but also major
bleeding events and stroke prevention depend on plasma concentrations of direct oral …

Direct oral anticoagulants (DOAC) have shown an upward prescribing trend in recent years
due to favorable pharmacokinetics and pharmacodynamics without requirement for routine …

Introduction Interindividual differences in drug response are a frequent clinical challenge
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …

Background Serious bleeding events have been frequently described in patients taking
direct oral anticoagulants (DOAC). In secondary analyses of phase 3 trials, DOAC plasma …

This study aimed to analyze associations between genetic variants and the occurrence of
clinical outcomes in dabigatran, apixaban, and rivaroxaban users. This was a retrospective …

Apixaban and rivaroxaban are the two most prescribed direct factor Xa inhibitors. With the
increased use of DOACs in real-world settings, safety and efficacy concerns have emerged …